Dr. Petr HausnerMedical Oncologist
Dr. Petr Hausner is chief of hematology and oncology at the Baltimore VA Medical Center, caring for patients with lung cancer and malignant pleural mesothelioma.
Get to Know Dr. Petr F. Hausner
Medical oncologist Dr. Petr Hausner is chief of hematology and oncology at the Baltimore VA Medical Center. He also treats patients at the University of Maryland Greenebaum Cancer Center in Baltimore, which includes a specialty department handling mesothelioma and other asbestos-related diseases.
Hausner is an associate professor at the University of Maryland School of Medicine, which he joined in 1998 after his fellowship at the nearby National Cancer Institute.
Born in Prague, in the former Czech Republic, Hausner started his career in the Laboratory of Clinical Immunology at First Faculty of Medicine, Charles University, where he earned his medical degree. He continued his studies in the United States.
His clinical work has focused on lung cancer, melanoma and mesothelioma. His laboratory interests involve cancer biology, molecular biology, DNA repair and the search for treatment advances.
Hausner joined the Baltimore VA Medical Center in 1999, overseeing much of the cancer-care operation. He has been a prolific researcher, contributing to seven medical textbooks and more than 130 abstracts, and also speaks five languages.
Specialties of Dr. Petr F. Hausner
- Thoracic oncology
- Bone and soft tissue oncology
- Gastrointestinal oncology
- Lung cancer
Dr. Petr F. Hausner’s Experience and Medical Education
- University of Maryland Greenebaum Cancer Center
- Baltimore VA Medical Center
- First Faculty of Medicine, Charles University
- National Institutes of Health (Fellowship)
- First Faculty of Medicine, Charles University (Residency and M.D.)
Awards and Certifications
- American Board of Medical Oncology
- American Board of Internal Medicine
- CMS Stage 1 EHR Certification
Publications of Dr. Petr F. Hausner
- Hausner, P. (2013, August). Image-guided Thermal Ablation of Tumor Increases the Plasma Level of Interleukin-6 and Interleukin-10: Is Plasma Level of Interleukin-6 a Surrogate for Immunogenic Cell Death? Journal of Vascular and Interventional Radiology.
- Reese, A.S. et al. (2013, January). Stereotactic Ablative Radiotherapy (SABR): Impact on the Immune System and Potential for Future Therapeutic Modulation. Molecular and Cellular Pharmacology.
- Hausner, P. et al. (1999, October). The “Comparative Growth Assay”: Examining the Interplay of Anti-cancer Agents with Cells Carrying Single Gene Alterations. Neoplasia.